Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Istradefylline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A known ✓ | P29274 | 7/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 2/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | MAOB | P27338 | 1/20 | 1.00 |
| ▸ | PDE4A | P27815 | 1/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Istradefylline SCHEMBL5967914 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA2BHTR1ACYP2C9 | |
| Istradefylline SCHEMBL30358491 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA2BHTR1ACYP2C9 | |
| Istradefylline SCHEMBL633263 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA2BHTR1ACYP2C9 | |
| Istradefylline SCHEMBL29471410 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA2BHTR1ACYP2C9 | |
| SCHEMBL14541714 | 0.96 | ADORA2A (0.92) | ADORA2AADORA3ADORA2BHTR1ACYP2C9 | |
| SCHEMBL2614707 | 0.94 | ADORA2A (0.88) | ADORA2AADORA3ADORA2BHTR1ACYP2C9 | |
| SCHEMBL25418285 | 0.93 | ADORA2A (0.87) | ADORA2AADORA3ADORA2BHTR1ACYP2C9 | |
| SCHEMBL25418282 | 0.93 | ADORA2A (0.87) | ADORA2AADORA3ADORA2BHTR1ACYP2C9 | |
| SCHEMBL25420003 | 0.92 | ADORA2A (0.85) | ADORA2AADORA3ADORA2BHTR1ACYP2C9 | |
| SCHEMBL7283401 | 0.92 | ADORA2A (0.85) | ADORA2AADORA3ADORA2BHTR1ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1976 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137689-A1 | INTEGRATION OF MOLECULAR MECHANISMS IN THE STRIATUM AS A COMBINATION DRUG STRATEGY FOR THE TREATMENT OF PSYCHIATRIC AND NEUROLOGICAL DISORDERS IN WHICH ANHEDONIA OR MOTIVATION-RELATED DYSFUNCTION EXISTS | ALTO NEUROSCIENCE INC (US) | 2026-05-21 | — | — | US | claimed |
| US-12629363-B2 | Prophylaxis and treatment of angioedema | PHARVARIS GMBH (CH) | 2026-05-19 | — | — | US | claimed |
| US-20260091047-A1 | THERAPEUTIC COMBINATIONS FOR MOVEMENT DISORDERS | NATIVE CODE BIO LLC (US) | 2026-04-02 | — | — | US | claimed |
| US-20260083740-A1 | USE OF TAVAPADON IN TREATING PARKINSON'S DISEASE | CEREVEL THERAPEUTICS LLC (US) | 2026-03-26 | — | — | US | claimed |
| EP-4704971-A1 | GAMMA STIMULATION AND NEUROMODULATOR COMBINATION THERAPY | Cognito Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4687683-A1 | CONTROL OF ULTRASOUND PROCEDURES BY MONITORING MICROBUBBLE RESPONSE | Insightec Ltd. (IL) | 2026-02-11 | — | — | EP | claimed |
| US-20260027178-A1 | Treatment Of Parkinson's Disease With SIM BHLH Transcription Factor 2 (SIM2) Agonists | REGENERON PHARMA (US) | 2026-01-29 | — | — | US | claimed |
| US-12527800-B2 | Therapeutic agent for Parkinson's disease | KYOWA KIRIN CO., LTD. (JP) | 2026-01-20 | — | — | US | claimed |
| EP-4676452-A1 | COMBINATION OF METFORMIN AND GLIBENCLAMIDE IN THE TREATMENT OF PARKINSON'S DISEASE | CXS Therapeutics (FR) | 2026-01-14 | — | — | EP | claimed |
| EP-4673215-A1 | GBA1 AND GCS DUAL MODULATOR | ONO Pharmaceutical Co., Ltd. (JP) | 2026-01-07 | — | — | EP | claimed |
| EP-1631294-A1 | A METHOD OF TREATING AN ANXIETY DISORDER | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-03-08 | — | — | EP | claimed |
| EP-1626049-A1 | MICROCRYSTAL | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-02-15 | — | — | EP | claimed |
| US-20060029663-A1 | Solid formulation | KYOWA HAKKO KOGYO CO., LTD (JP) | 2006-02-09 | — | — | US | claimed |
| US-20050245545-A1 | Adenosine a2s receptor antagonists for treating restless legs syndrome or related disorders | KYOWA HAKKO KOGYO CO., LTD (JP) | 2005-11-03 | — | — | US | claimed |
| EP-1581163-A2 | USE OF ISTRADEFYLLINE (KW-6002) FOR THE TREATMENT OF BEHAVIORAL DISORDERS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2005-10-05 | — | — | EP | claimed |
| WO-2004108137-A1 | A METHOD OF TREATING AN ANXIETY DISORDER | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-12-16 | — | — | WO | claimed |
| EP-1469855-A2 | METHODS OF TREATING PATIENTS SUFFERING FROM MOVEMENT DISORDERS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-10-27 | — | — | EP | claimed |
| US-20040198753-A1 | administering adenosine receptor antagonist ; side effect reduction; parkinson's disease | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2004-10-07 | — | — | US | claimed |
| WO-2004058139-A2 | USE OF ISTRADEFYLLINE (KW-6002) FOR THE TREATMENT OF BEHAVIORAL DISORDERS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-07-15 | — | — | WO | claimed |
| WO-2003063876-A2 | METHODS OF TREATING PATIENTS SUFFERING FROM MOVEMENT DISORDERS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2003-08-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245545-A1 | Adenosine a2s receptor antagonists for treating restless legs syndrome or related disorders | ADORA2A, ADORA2B, ADORA3 | ADORA2A 1/4885ADORA3 3/4885ADORA2B 2/4885 |
| US-20260137689-A1 | INTEGRATION OF MOLECULAR MECHANISMS IN THE STRIATUM AS A COMBINATION DRUG STRATEGY FOR THE TREATMENT OF PSYCHIATRIC AND NEUROLOGICAL DISORDERS IN WHICH ANHEDONIA OR MOTIVATION-RELATED DYSFUNCTION EXISTS | CHRNA5, CHRNA2, CHRNA4 | ADORA2A 5/4885ADORA3 24/4885ADORA2B 7/4885 |
| US-20260083740-A1 | USE OF TAVAPADON IN TREATING PARKINSON'S DISEASE | SNCA, DRD2, DRD1 | ADORA2A 126/4885ADORA3 202/4885ADORA2B 492/4885 |
| US-20260091047-A1 | THERAPEUTIC COMBINATIONS FOR MOVEMENT DISORDERS | HMBS, SNCA, PYGB | ADORA2A 241/4885ADORA3 442/4885ADORA2B 71/4885 |
| US-20260027178-A1 | Treatment Of Parkinson's Disease With SIM BHLH Transcription Factor 2 (SIM2) Agonists | PARK7, SNCA, LRRK2 | ADORA2A 4021/4885ADORA3 4100/4885ADORA2B 4140/4885 |
| US-20040198753-A1 | administering adenosine receptor antagonist ; side effect reduction; parkinson's disease | ADORA2A, COMT, MAOA | ADORA2A 1/4885ADORA3 5/4885ADORA2B 4/4885 |
| US-12527800-B2 | Therapeutic agent for Parkinson's disease | PARK7, SNCA, COMT | ADORA2A 64/4885ADORA3 201/4885ADORA2B 437/4885 |
| US-20060029663-A1 | Solid formulation | F12, DCXR, XDH | ADORA2A 599/4885ADORA3 197/4885ADORA2B 754/4885 |
| US-12629363-B2 | Prophylaxis and treatment of angioedema | BDKRB2, BDKRB1, HRH2 | ADORA2A 454/4885ADORA3 290/4885ADORA2B 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.